Abiraterone Acetate is mainly used to treat prostate cancer in men, particularly those with metastatic castration-resistant prostate cancer (mCRPC) or metastatic castration-sensitive prostate cancer (mCSPC). It works by inhibiting the production of androgens (male hormones), which play a key role in the growth of prostate cancer cells. The medication is typically given along with prednisone or prednisolone to help manage side effects and enhance its effectiveness. It is often prescribed to patients who have not responded well to chemotherapy or are unable to undergo chemotherapy.

Abiraterone Acetate works by blocking the CYP17A1 enzyme, which lowers androgen (male hormone) levels in the body. This drop in hormones slows the growth of prostate cancer cells, making it effective in advanced prostate cancer.

Abiraterone Acetate tablets are taken orally once daily on an empty stomach either 1 hour before or 2 hours after a meal. They should be swallowed whole with water and are usually given along with low-dose prednisone. The doctor decides the dosage and duration, and regular monitoring of liver function, blood pressure, and electrolytes is advised during treatment.

Common side effects of Abiraterone Acetate include high blood pressure, low potassium, fluid retention, fatigue, and joint pain. Some patients may also experience diarrhea, hot flashes, or increased liver enzymes. Serious but less common effects include liver problems, irregular heartbeat, and adrenal issues. Regular monitoring is important during treatment.

Abiraterone Acetate should be avoided in severe liver disease and used cautiously in patients with heart issues, high blood pressure, or electrolyte imbalances. Regular monitoring of liver function, blood pressure, and potassium is essential. It must be taken with a corticosteroid to prevent adrenal problems and always on an empty stomach to avoid excess absorption. This medicine is not recommended for women or children.

Abiraterone Acetate is an effective oral treatment for advanced prostate cancer, helping slow disease progression by reducing androgen production. When combined with corticosteroids, it offers a well-tolerated option for patients who may not respond to chemotherapy. Although monitoring is important due to possible side effects, it remains a key therapy in modern prostate cancer care.

Unlike traditional hormone therapies that reduce testosterone production in the testes, Abiraterone Acetate blocks androgen production at multiple sites, including the adrenal glands and the tumor itself, offering a more complete androgen blockade.

Abiraterone inhibits the CYP17 enzyme, which may lead to an increase in mineralocorticoid levels, causing side effects like hypertension, fluid retention, and hypokalemia. Prednisone or prednisolone helps counteract these effects and reduces the risk of adrenal insufficiency.

Abiraterone is generally reserved for advanced or metastatic prostate cancer (mCRPC or mCSPC). Its use in early-stage prostate cancer is not standard and should be guided by clinical judgment and specific patient factors.

Patients should undergo regular monitoring of liver function tests, serum potassium, blood pressure, and signs of fluid retention. Monitoring helps in early detection of adverse effects and ensures safe, ongoing treatment.

Yes. Abiraterone must be taken on an empty stomach at least 1 hour before or 2 hours after a meal as food significantly increases its absorption, which can increase the risk of side effects.

Treatment duration varies based on individual response and tolerance. Patients typically continue therapy as long as the cancer is controlled and side effects are manageable. Discontinuation is considered if the disease progresses or adverse effects become severe.

Yes. Abiraterone is approved for use in patients with mCRPC who have previously received docetaxel-based chemotherapy, and has shown survival benefits in such cases.

Yes. Abiraterone may interact with drugs that are substrates of CYP3A4, CYP2D6, and other liver enzymes. Caution is advised when using medications such as certain antihypertensives, sedatives, or antiepileptics.

Caution is required in patients with liver impairment. It is contraindicated in severe liver dysfunction, and dose adjustments or close monitoring may be needed in mild to moderate cases.

Patients should seek immediate medical help if they experience severe dizziness, swelling in the legs, shortness of breath, irregular heartbeat, signs of liver damage (yellowing of skin/eyes, dark urine), or muscle weakness due to low potassium.